Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trans fatty acids

This article was originally published in The Tan Sheet

Executive Summary

Small entity compliance guide on "Food Labeling: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims" available, FDA announces Aug. 20. Guide is "intended to help small businesses understand" trans fat final rule and "to set forth in plain language the requirements of the regulation." FDA invites comments on 1SECG at any time. Rule was published in July 11 Federal Register (2"The Tan Sheet" July 14, 2003, p.7)...

You may also be interested in...



Supplement Trans Fat Label Additions Stipulated Under FDA Final Rule

Manufacturers of dietary supplements that contain more than .5 g of trans fat will be required to list the amount of the ingredient, as well as the amounts of saturated fat and cholesterol, on the Supplement Facts panel by Jan. 1, 2006

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel